PET Scan
Case Report: Immune checkpoint inhibitor-triggered anti-Ma2 paraneoplastic encephalitis in sarcomatoid pleural mesothelioma: a fatal case
Frontiers in Oncology 2026 March 9 [Link] Ilker Nihat Okten, Tuba Baydaş Abstract Background: Neurological immune-related adverse events (N-irAEs) represent rare but potentially fatal complications of immune checkpoint inhibitor (ICI) therapy. Among these, encephalitis associated with paraneoplatic neuronal antibodies poses a major diagnostic and therapeutic challenge, as it blurs the distinction between drug-induced toxicity and…
Read MorePretreatment volume-based 18F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients
Japanese Journal of Radiology 2026 March 21 [Link] Kazuhiro Kitajima, Kosuke Matsuda, Hiroyuki Yokoyama, Toshiyuki Minami, Akifumi Nakamura, Kozo Kuribayashi, Takashi Kijima, Koichiro Yamakado Abstract Objective: This study was conducted to examine relationships of pretreatment volume-based quantitative 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) parameters with overall survival (OS) in malignant peritoneal mesothelioma (MPeM) patients.…
Read MoreMalignant Pleural Mesothelioma (MPM) Evaluation with [11C]-Methionine PET/CT Before and After Talc Pleurodesis
Molecular Imaging and Biology 2026 March 9 [Link] Egesta Lopci, Angelo Castello, Alberto Testori, Emanuele Voulaz, Daoud Rahal 5, Matteo Perrino 6, Alessandro Crepaldi 3, Giorgio Maria Ferraroli 3, Valentina Errico 3, Edoardo Bottoni 3, Marcello Rodari 7, Lorenzo Muraglia 2, Giuseppe Marulli 3 4, Marco Alloisio, Paolo Andrea Zucali Abstract Background: Malignant pleural mesothelioma…
Read MoreBAP-1 in the diagnosis of malignant pleural mesothelioma
Respiratory Medicine and Research 2025 November 28 [Link] Irene Sansano, Ana Vázquez, Oscar Persiva, Marc Simó, Leire Sánchez, Pilar Montoya, Carme Dinarès, Carmen Alemán Abstract Background: The diagnosis of malignant pleural mesothelioma (MPM) can be challenging for clinicians and pathologists. Patients and methods: This study included all patients diagnosed with pleural mesothelioma between October 2013…
Read MoreDisaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 February 2 [Link] Shubham Gulati, Andrea Wolf, Jai Mehrotra-Varma, Stephanie Tuminello, Emanuela Taioli, Raja Flores Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS2) trial has drawn into question pleurectomy/decortication (PD) for the treatment of pleural mesothelioma. This trial’s evaluation of resectability (poor positron emission tomography/computed tomography utilization, patients…
Read MoreArtificial Intelligence in Pleural Diseases: Current Applications and Next Steps
Thoracic Research and Practice 2026 January 30 [Link] Ferhan Karataş, Öner Dikensoy Abstract Pleural diseases pose a significant burden on healthcare systems due to diagnostic challenges and high costs. Artificial intelligence (AI) has the potential to provide faster, more accurate, and more reliable results in the diagnosis of these diseases. This review evaluates the current…
Read MorePleural Mesothelioma Diagnosis for the Pulmonologist: Steps Along the Way
Cancers 2025 December 1 [Link] Alberto Fantin, Nadia Castaldo, Ernesto Crisafulli, Giulia Sartori, Filippo Patrucco, Horiana B Grosu, Paolo Vailati, Giuseppe Morana, Vincenzo Patruno, Stefano Kette, Avinash Aujayeb, Aleš Rozman Abstract Background/Objectives: Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis and complex diagnostic pathways. Pulmonologists often play a central role…
Read MorePositron emission tomography/computed tomography in risk-factor-negative young female with malignant pleural mesothelioma: A case report and review of literature
World Journal of Clinical Cases 2025 November 16 [Link] Aikedan Aisikaer, Mo-Mo Sun, Jie Shen Abstract Background: Malignant pleural mesothelioma (MPM), a rare aggressive malignancy, is primarily caused by asbestos exposure. MPM typically affects older adults (median age, 76 years), is uncommon in those under age 50 years and shows male predominance. Based on the…
Read MoreEnhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68 Ga-FAPI PET/CT Compared to 18 F-FDG PET/CT: A Case Report
World Journal of Nuclear Medicine 2025 March 12 [Link] Marwah Abdulrahman, Ula Al-Rasheed, Ali Dabous, Akram Al-Ibraheem Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid mesothelioma that arises from the lining of the abdominal cavity. While the applications of traditional fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography…
Read MoreSignificance of 18F-fluorodeoxyglucose PET/computed tomography in the initial staging of malignant peritoneal mesothelioma
Nuclear Medicine Communications 2025 May 6 [Link] Hui Zhang, Lifang Pang, Jun Hou, Beilei Li, Yiqiu Zhang Abstract Objective: This study was aimed at evaluating the significance of 18F-fluorodeoxyglucose PET/computed tomography (FDG PET/CT) in the staging and differentiation of malignant peritoneal mesothelioma (MPeM). Materials and methods: We retrospectively analyzed clinical and imaging data of 21…
Read More
Skip to content